These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 11231705)
21. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429 [TBL] [Abstract][Full Text] [Related]
22. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin. Ramirez JA; Cooper AC; Wiemken T; Gardiner D; Babinchak T; BMC Infect Dis; 2012 Jul; 12():159. PubMed ID: 22812672 [TBL] [Abstract][Full Text] [Related]
23. When to switch therapy in patients with severe community-acquired pneumonia. Mortensen EM; Restrepo MI; Anzueto A Ann Intern Med; 2008 Apr; 148(8):625; author reply 625-6. PubMed ID: 18413627 [No Abstract] [Full Text] [Related]
24. Achieving a safe and early discharge for patients with community-acquired pneumonia. Rhew DC; Weingarten SR Med Clin North Am; 2001 Nov; 85(6):1427-40. PubMed ID: 11686189 [TBL] [Abstract][Full Text] [Related]
25. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Muszynski JA; Knatz NL; Sargel CL; Fernandez SA; Marquardt DJ; Hall MW Pediatr Infect Dis J; 2011 Apr; 30(4):295-301. PubMed ID: 21030885 [TBL] [Abstract][Full Text] [Related]
27. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB; Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688 [TBL] [Abstract][Full Text] [Related]
28. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679 [TBL] [Abstract][Full Text] [Related]
29. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Griffin AT; Peyrani P; Wiemken T; Arnold F Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309 [TBL] [Abstract][Full Text] [Related]
30. Community-acquired pneumonia: influence of management practices on length of hospital stay. Laing R; Coles C; Chambers S; Frampton C; Jennings L; Karalus N; Mills G; Town GI Intern Med J; 2004 Mar; 34(3):91-7. PubMed ID: 15030455 [TBL] [Abstract][Full Text] [Related]
31. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan. Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247 [TBL] [Abstract][Full Text] [Related]
33. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy. Ramirez JA Pharmacotherapy; 2001 Jul; 21(7 Pt 2):79S-82S. PubMed ID: 11446522 [TBL] [Abstract][Full Text] [Related]
34. [Switch therapy for community acquired pneumonia]. Aoshima M Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():326-30. PubMed ID: 17455640 [No Abstract] [Full Text] [Related]
36. Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Cunha BA Am J Med; 2001 Oct; 111(5):412-3. PubMed ID: 11583649 [No Abstract] [Full Text] [Related]
37. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia. Lindstrom ST; Wong EK Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892 [TBL] [Abstract][Full Text] [Related]
38. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492 [TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Dresser LD; Niederman MS; Paladino JA Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951 [TBL] [Abstract][Full Text] [Related]
40. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. Feagan BG; Marrie TJ; Lau CY; Wheeler SL; Wong CJ; Vandervoort MK CMAJ; 2000 May; 162(10):1415-20. PubMed ID: 10834044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]